Characterization of an ovarian carcinoma cell line resistant to cisplatin and flavopiridol. 2000

K C Bible, and S A Boerner, and K Kirkland, and K L Anderl, and D Bartelt, and P A Svingen, and T J Kottke, and Y K Lee, and S Eckdahl, and P G Stalboerger, and R B Jenkins, and S H Kaufmann
Division of Medical Oncology, Mayo Clinic, Rochester, MN 55905, USA.

Flavopiridol, the first inhibitor of cyclin-dependent kinases to enter clinical trials, has shown promising antineoplastic activity and is currently undergoing Phase II testing. Little is known about mechanisms of resistance to this agent. In the present study, we have characterized an ovarian carcinoma cell line [OV202 high passage (hp)] that spontaneously developed drug resistance upon prolonged passage in tissue culture. Standard cytogenetic analysis and spectral karyotyping revealed that OV202 hp and the parental low passage line OV202 shared several marker chromosomes, confirming the relatedness of these cell lines. Immunoblotting demonstrated that OV202 and OV202 hp contained similar levels of a variety of polypeptides involved in cell cycle regulation, including cyclin-dependent kinases 2 and 4; cyclins A, D1, and E; and proliferating cell nuclear antigen. Despite these similarities, OV202 hp was resistant to flavopiridol and cisplatin, with increases of 5- and 3-fold, respectively, in the mean drug concentrations required to inhibit colony formation by 90%. In contrast, OV202 hp and OV202 displayed indistinguishable sensitivities to oxaliplatin, paclitaxel, topotecan, 1,3-bis(2-chloroethyl)-1-nitrosourea, etoposide, doxorubicin, vincristine, and 5-fluorouracil, suggesting that the spontaneously acquired resistance was not attributable to altered P-glycoprotein levels or a general failure to engage the cell death machinery. After incubation with cisplatin, whole cell platinum and platinum-DNA adducts measured using mass spectrometry were lower in OV202 hp cells than OV202 cells. Similarly, after flavopiridol exposure, whole cell flavopiridol concentrations measured by a newly developed high performance liquid chromatography assay were lower in OV202 hp cells. These data are consistent with the hypothesis that acquisition of spontaneous resistance to flavopiridol and cisplatin in OV202 hp cells is due, at least in part, to reduced accumulation of the respective drugs. These observations not only provide the first characterization of a flavopiridol-resistant cell line but also raise the possibility that alterations in drug accumulation might be important in determining sensitivity to this agent.

UI MeSH Term Description Entries
D007621 Karyotyping Mapping of the KARYOTYPE of a cell. Karyotype Analysis Methods,Analysis Method, Karyotype,Analysis Methods, Karyotype,Karyotype Analysis Method,Karyotypings,Method, Karyotype Analysis,Methods, Karyotype Analysis
D009944 Organoplatinum Compounds Organic compounds which contain platinum as an integral part of the molecule. Compounds, Organoplatinum
D010051 Ovarian Neoplasms Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS. Cancer of Ovary,Ovarian Cancer,Cancer of the Ovary,Neoplasms, Ovarian,Ovary Cancer,Ovary Neoplasms,Cancer, Ovarian,Cancer, Ovary,Cancers, Ovarian,Cancers, Ovary,Neoplasm, Ovarian,Neoplasm, Ovary,Neoplasms, Ovary,Ovarian Cancers,Ovarian Neoplasm,Ovary Cancers,Ovary Neoplasm
D010880 Piperidines A family of hexahydropyridines.
D002330 Carmustine A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed) BCNU,1,3-Bis(2-Chloroethyl)-1-Nitrosourea,BiCNU,FIVB,N,N'-Bis(2-Chloroethyl)-N-Nitrosourea,Nitrumon
D002869 Chromosome Aberrations Abnormal number or structure of chromosomes. Chromosome aberrations may result in CHROMOSOME DISORDERS. Autosome Abnormalities,Cytogenetic Aberrations,Abnormalities, Autosome,Abnormalities, Chromosomal,Abnormalities, Chromosome,Chromosomal Aberrations,Chromosome Abnormalities,Cytogenetic Abnormalities,Aberration, Chromosomal,Aberration, Chromosome,Aberration, Cytogenetic,Aberrations, Chromosomal,Aberrations, Chromosome,Aberrations, Cytogenetic,Abnormalities, Cytogenetic,Abnormality, Autosome,Abnormality, Chromosomal,Abnormality, Chromosome,Abnormality, Cytogenetic,Autosome Abnormality,Chromosomal Aberration,Chromosomal Abnormalities,Chromosomal Abnormality,Chromosome Aberration,Chromosome Abnormality,Cytogenetic Aberration,Cytogenetic Abnormality
D002874 Chromosome Mapping Any method used for determining the location of and relative distances between genes on a chromosome. Gene Mapping,Linkage Mapping,Genome Mapping,Chromosome Mappings,Gene Mappings,Genome Mappings,Linkage Mappings,Mapping, Chromosome,Mapping, Gene,Mapping, Genome,Mapping, Linkage,Mappings, Chromosome,Mappings, Gene,Mappings, Genome,Mappings, Linkage
D002945 Cisplatin An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle. Platinum Diamminodichloride,cis-Diamminedichloroplatinum(II),cis-Dichlorodiammineplatinum(II),Biocisplatinum,Dichlorodiammineplatinum,NSC-119875,Platidiam,Platino,Platinol,cis-Diamminedichloroplatinum,cis-Platinum,Diamminodichloride, Platinum,cis Diamminedichloroplatinum,cis Platinum
D005260 Female Females
D005419 Flavonoids A group of phenyl benzopyrans named for having structures like FLAVONES. 2-Phenyl-Benzopyran,2-Phenyl-Chromene,Bioflavonoid,Bioflavonoids,Flavonoid,2-Phenyl-Benzopyrans,2-Phenyl-Chromenes,2 Phenyl Benzopyran,2 Phenyl Benzopyrans,2 Phenyl Chromene,2 Phenyl Chromenes

Related Publications

K C Bible, and S A Boerner, and K Kirkland, and K L Anderl, and D Bartelt, and P A Svingen, and T J Kottke, and Y K Lee, and S Eckdahl, and P G Stalboerger, and R B Jenkins, and S H Kaufmann
November 1978, Cancer,
K C Bible, and S A Boerner, and K Kirkland, and K L Anderl, and D Bartelt, and P A Svingen, and T J Kottke, and Y K Lee, and S Eckdahl, and P G Stalboerger, and R B Jenkins, and S H Kaufmann
January 1998, Chemotherapy,
K C Bible, and S A Boerner, and K Kirkland, and K L Anderl, and D Bartelt, and P A Svingen, and T J Kottke, and Y K Lee, and S Eckdahl, and P G Stalboerger, and R B Jenkins, and S H Kaufmann
January 2009, Saudi medical journal,
K C Bible, and S A Boerner, and K Kirkland, and K L Anderl, and D Bartelt, and P A Svingen, and T J Kottke, and Y K Lee, and S Eckdahl, and P G Stalboerger, and R B Jenkins, and S H Kaufmann
May 1996, Cancer,
K C Bible, and S A Boerner, and K Kirkland, and K L Anderl, and D Bartelt, and P A Svingen, and T J Kottke, and Y K Lee, and S Eckdahl, and P G Stalboerger, and R B Jenkins, and S H Kaufmann
September 1996, International journal of cancer,
K C Bible, and S A Boerner, and K Kirkland, and K L Anderl, and D Bartelt, and P A Svingen, and T J Kottke, and Y K Lee, and S Eckdahl, and P G Stalboerger, and R B Jenkins, and S H Kaufmann
November 2001, Molecular pharmacology,
K C Bible, and S A Boerner, and K Kirkland, and K L Anderl, and D Bartelt, and P A Svingen, and T J Kottke, and Y K Lee, and S Eckdahl, and P G Stalboerger, and R B Jenkins, and S H Kaufmann
June 1992, Cancer research,
K C Bible, and S A Boerner, and K Kirkland, and K L Anderl, and D Bartelt, and P A Svingen, and T J Kottke, and Y K Lee, and S Eckdahl, and P G Stalboerger, and R B Jenkins, and S H Kaufmann
July 2015, DNA and cell biology,
K C Bible, and S A Boerner, and K Kirkland, and K L Anderl, and D Bartelt, and P A Svingen, and T J Kottke, and Y K Lee, and S Eckdahl, and P G Stalboerger, and R B Jenkins, and S H Kaufmann
November 2005, Oncology reports,
K C Bible, and S A Boerner, and K Kirkland, and K L Anderl, and D Bartelt, and P A Svingen, and T J Kottke, and Y K Lee, and S Eckdahl, and P G Stalboerger, and R B Jenkins, and S H Kaufmann
January 1994, Cancer chemotherapy and pharmacology,
Copied contents to your clipboard!